Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives Hussack G; Tanha JToxins (Basel) 2010[May]; 2 (5): 998-1018Therapeutic agents targeting bacterial virulence factors are gaining interest as non-antibiotic alternatives for the treatment of infectious diseases. Clostridium difficile is a Gram-positive pathogen that produces two primary virulence factors, enterotoxins A and B (TcdA and TcdB), which are responsible for Clostridium difficile-associated disease (CDAD) and are targets for CDAD therapy. Antibodies specific for TcdA and TcdB have been shown to effectively treat CDAD and prevent disease relapse in animal models and in humans. This review summarizes the various toxin-specific antibody formats and strategies under development, and discusses future directions for CDAD immunotherapy, including the use of engineered antibody fragments with robust biophysical properties for systemic and oral delivery.|Animals[MESH]|Antibodies, Bacterial/immunology[MESH]|Antibodies/*pharmacology[MESH]|Bacterial Proteins/*immunology[MESH]|Bacterial Toxins/*immunology[MESH]|Clostridioides difficile/immunology/*pathogenicity[MESH]|Disease Models, Animal[MESH]|Enterocolitis, Pseudomembranous/drug therapy/immunology[MESH]|Enterotoxins/*immunology[MESH]|Humans[MESH]|Immunotherapy/*methods/trends[MESH]|Recombinant Proteins/pharmacology[MESH]|Virulence Factors[MESH] |
